Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Dec 5;35(5):498–505. doi: 10.1200/JCO.2016.67.4119

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 by American Society of Clinical Oncology

PMC Copyright notice

Fig 1. — Graphical representation of the trial network for overall and progression-free survival. The size of the nodes is proportional to the number of patients (pts), which is given in parenthesis in each treatment category. The width of the lines is proportional to the number of comparisons. The number of trials (t) and pts in each comparison are displayed next to each line. The network included 26 comparisons from 20 trials. Six comparisons were counted for the QMH-95 trial (2 × 2 design) and two for the NPC-9902 trial (2 × 2 design; second randomization on radiotherapy [RT] modalities). Because of the duplication of QMH-95 trial arms, some pts are counted multiple times in this figure (in the RT, concomitant chemoradiotherapy [CRT], CRT-adjuvant chemotherapy [AC], and RT-AC groups). However, the statistical analysis takes into account the correlation structure in this design and does not give an excessive weight to duplicated patients. IC, induction chemotherapy.